Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Wed, 11.12.2024       Formycon AG

Company Name: Formycon AG ISIN: DE000A1EWVY8   Reason for the research: Update Recommendation: Buy from: 11.12.2024 Target price: €82 Target price on sight of: 12 months Last rating change: - Analyst: Simon Scholes First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analyst Simo [ … ]
Mon, 09.12.2024       Formycon AG

Presse Release // December 09, 2024   MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Planegg-Martinsried, Germany / Amman, Jodan – Formycon AG (FSE: FYB, Prime Standard) and MS Pharma jointly announce that they have entered into a licensing and supply agreement for the commercialization of FYB202, F [ … ]
Thu, 05.12.2024       Formycon AG

Press Release // December 5, 2024 Formycon joins the SDAX of the German Stock Exchange Formycon shares will be part of the DAX index family, ranking among the 70 largest German companies below the MDAX Enhanced share attractiveness following recent uplisting to the Prime Standard Formycon shares to be included in the index effective as of Decem [ … ]
Thu, 28.11.2024       Formycon AG

Press Release // November 28, 2024   Formycon reports nine-month results for 2024 and continues growth trajectory with further operational success Excellent third quarter with product approvals for FYB202 in the key markets USA and Europe Keytruda® biosimilar candidate FYB206 starts clinical development program (phase I and phase III study) Dev [ … ]
Tue, 19.11.2024       Formycon AG

Press Release // November 19, 2024 Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, „Formycon“) invites to the conference call and webcast for the publication of the nine-month results 2024 on November 28, 2024. [ … ]
Mon, 18.11.2024       Formycon AG

Press Release // November 18, 2024   Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommends approval of FYB203 for the treatment of Neovascular Age-Related  [ … ]
Fri, 15.11.2024       Formycon AG

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014   Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA   Planegg-Martinsried, Germany, November 15, 2024 – Formycon (FSE: FYB, "Formycon“) announces that the European Medicines Agency (EMA) published today that the Co [ … ]
Mon, 11.11.2024       Formycon AG

Press Release // November 11, 2024Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard  Dr. Stefan Glombitza has been appointed as CEO for three more years and will lead Formycon through the next phase of the company's development Formycon shares will be admitt [ … ]
Mon, 04.11.2024       Formycon AG

Press Release // November 04, 2024 Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange Application for admission to trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange will be submitted today Trading of Formycon shares on the Prime Standard segment is expected to start on November 12, [ … ]
Wed, 16.10.2024       Formycon AG

Press Release // October 16, 2024   Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D   The comparative analytical evaluation results indicate that the proposed Keytruda®-biosimilar FYB206 is structurally and functionally highly similar to the reference [ … ]

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Tuesday, 24.12.2024, Calendar Week 52, 359th day of the year, 7 days remaining until EoY.